Costs and Consequences of Using Interferon-γ Release Assays for the Diagnosis of Active Tuberculosis

Published Date:

04/28/2015

Source:

PubMed - NCBI

Authors:

Little KM, Pai M, Dowdy DW

External link

Original Article

There is growing concern that interferon-γ release assays (IGRAs) are being used off-label for the diagnosis of active tuberculosis (TB) disease in many high-burden settings, including India, where the background prevalence of latent TB infection is high. We analyzed the costs and consequences of using IGRAs for the diagnosis of active TB in India from the perspective of the Indian TB control sector.

Events

«

July 2017

»
S
M
T
W
T
F
S
·
·
·
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
·
·
·
·
·

Projects

TBM-KIDS (Malawi)

A phase 2 clinical trial of optimized treatment for pediatric tuberculous meningitis in India and Malawi

Read More

Understanding the role of repeat testing and...

We have developed a Markov model of serial IGRA testing to help improve testing algorithms with TST vs. IGRA in low-risk...

Read More

Understanding the impact of combined TB and...

We are developing models to understand the overlap of TB and HIV in three epidemiologically distinct settings (Canada, India,...

Read More

A randomized trial of preventive therapy for...

We are evaluating the efficacy and cost-effectiveness of levofloxacin preventive therapy for adult contacts of MDR TB patients...

Read More